


Am



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 199 372 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
24.04.2002 Bulletin 2002/17

(51) Int Cl.7: **C12Q 1/68**, C07K 16/28,
C07K 14/705, C12N 15/12

(21) Application number: **01308837.2**

(22) Date of filing: **17.10.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **21.10.2000 GB 0025859**
06.04.2001 GB 0108654
02.11.2000 US 244897 P

(71) Applicant: **AstraZeneca AB**
151 85 Södertälje (SE)

(72) Inventor: **Morten, John Edward Norris**
Cheshire SK10 4TG (GB)

(74) Representative: **Giles, Allen Frank et al**
AstraZeneca,
Global Intellectual Property Patents,
Mereside,
Alderley Park
Macclesfield, Cheshire SK10 4TG (GB)

(54) **Polymorphisms in the human P2X7 gene**

(57) This invention relates to polymorphisms in the human P2X₇ gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic var-

iation in the P2X₇ gene, and to the use of P2X₇ polymorphism in treatment of diseases with P2X₇ drugs.

EP 1 199 372 A2

Description

[0001] This invention relates to polymorphisms in the human P2X₇ gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the P2X₇ gene, and to the use of P2X₇ polymorphism in treatment of diseases with P2X₇ drugs.

[0002] The P2X₇ receptor (previously known as P2Z receptor), which is a ligand-gated ion channel, is present on a variety of cell types, largely those known to be involved in the inflammatory/immune process, specifically, macrophages, mast cells and lymphocytes (T and B). Activation of the P2X₇ receptor by extracellular nucleotides, in particular adenosine triphosphate, leads to the release of interleukin-1 β (IL-1 β) and giant cell formation (macrophages/microglial cells), degranulation (mast cells) and L-selectin shedding (lymphocytes). P2X₇ receptors are also located on antigen-presenting cells (APC), keratinocytes, salivary acinar cells (parotid cells) and hepatocytes. Compounds acting at the P2X₇ receptor are therefore indicated as pharmaceuticals for use in the treatment of rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), hyperresponsiveness of the airway, septic shock, glomerulonephritis, irritable bowel disease, Crohn's disease, ulcerative colitis, atherosclerosis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, Alzheimer's disease, meningitis, osteoporosis, burn injury, ischaemic heart disease, stroke and varicose veins. For further background, the reader is referred to the following articles: North and Barnard in *Current Opinion in Neurobiology* 1997, **7**, 346-357; Rassendren, *JBC*, 1997, **273**, 5482-6; and Buell, *Receptors and Channels*, 1998, **5**, 347-354. The terms P2X₇, P2X₇ receptor and P2RX7 are used interchangeably herein.

[0003] All positions herein of polymorphisms in the 5' UTR region of the P2X₇ polynucleotide relate to the position in SEQ ID NO 1 unless stated otherwise or apparent from the context.

[0004] All positions herein of polymorphisms in the exon regions of the P2X₇ polynucleotide relate to the position in SEQ ID NO 2 unless stated otherwise or apparent from the context.

[0005] All positions herein of polymorphisms in the intron regions of the P2X₇ polynucleotide relate to the position in SEQ ID NO 3 unless stated otherwise or apparent from the context.

[0006] All positions herein of polymorphisms in the P2X₇ polypeptide relate to the position in SEQ ID NO 4 unless stated otherwise or apparent from the context.

[0007] One approach is to use knowledge of polymorphisms to help identify patients most suited to therapy with particular pharmaceutical agents (this is often termed "pharmacogenetics"). Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997), *Clinical Chemistry*, **43**, 254; Marshall (1997), *Nature Biotechnology*, **15**, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer *et al.* (1998), *Nature Biotechnology*, **16**, 33.

[0008] Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design and therapy.

[0009] Point mutations in polypeptides will be referred to as follows: natural amino acid (using 1 or 3 letter nomenclature), position, new amino acid. For (a hypothetical) example "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual mutations separated by commas.

[0010] The present invention is based on the discovery of polymorphisms in P2X₇. In particular, we have found thirty polymorphisms in the coding sequence of the P2X₇ gene, 12 of which lead to changes in the sequence of expressed protein.

[0011] According to one aspect of the present invention there is provided a method for the diagnosis of a polymorphism in P2X₇ in a human, which method comprises determining the sequence of the human at at least one polymorphic position and determining the status of the human by reference to polymorphism in P2X₇. Preferred polymorphic positions are one or more of the following positions:

positions 936, 1012, 1147, 1343 and 1476 in the 5'UTR region of the P2X₇ gene as defined by the position in SEQ ID NO: 1;

positions 253, 488, 489, 760, 835, 853, 1068, 1096, 1315, 1324, 1405, 1448, 1494, 1513, 1628 and 1772 in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2; and positions 4780, 4845, 4849, 5021, 5554, 5579, 5535, 5845 and 6911 in the intron region of the P2X₇ gene as defined by the position in SEQ ID NO: 3;

positions 76, 155, 245, 270, 276, 348, 357, 430, 433, 460, 490 and 496 in the P2X₇ polypeptide as defined by the position in SEQ ID NO: 4.

[0012] The term human includes both a human having or suspected of having a P2X₇ mediated disease and an

asymptomatic human who may be tested for predisposition or susceptibility to such disease. At each position the human may be homozygous for an allele or the human may be a heterozygote.

[0013] The term "status" refers to the genetic status of the human as detected by potential sequence variation at defined positions of a polynucleotide or corresponding protein. The term "diagnosis of a polymorphism" refers to determination of the genetic status of an individual at a polymorphic position (in which the individual may be homozygous or heterozygous at each position).

[0014] The term polymorphism includes single nucleotide substitution, nucleotide insertion and nucleotide deletion which in the case of insertion and deletion includes insertion or deletion of one or more nucleotides at a position of a gene and corresponding alterations in expressed protein.

[0015] In one embodiment of the invention preferably the method for diagnosis described herein is one in which the polymorphism in the in the 5'UTR region of the P2X₇ gene as defined by the position in SEQ ID NO: 1 is any one of the following:

at position 936 is presence of C and/or A; at position 1012 is presence of T and/or C;
at position 1147 is presence of A and/or G; at position 1343 is presence of G and/or A; and
at position 1476 is presence of A and/or G.

[0016] In one embodiment of the invention preferably the method for diagnosis described herein is one in which the polymorphism in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2 is any one of the following:

at position 253 is presence of T and/or C; at position 488 is presence of G and/or A;
at position 489 is presence of C and/or T; at position 760 is presence of T and/or G;
at position 835 is presence of G and/or A; at position 853 is presence of G and/or A;
at position 1068 is presence of G and/or A; at position 1096 is presence of C and/or G;
at position 1315 is presence of C and/or G; at position 1324 is presence of C and/or T;
at position 1405 is presence of A and/or G; at position 1448 is presence of C and/or T;
at position 1494 is presence of A and/or G; at position 1513 is presence of A and/or C;
at position 1628 is presence of G and/or T; and at position 1772 is presence of G and/or A.

[0017] In one embodiment of the invention preferably the method for diagnosis described herein is one in which the polymorphism in the intron region of the P2X₇ gene as defined by the position in SEQ ID NO: 3. is any one of the following:

at position 4780 is presence of C and/or T; at position 4845 is presence of C and/or T;
at position 4849 is presence of A and/or C; at position 5021 is presence of T and/or C;
at position 5554 is presence of 3 and/or 4 repeats of GTTT (wherein position 5554 refers to the position of the G in the first unit repeat);
at position 5579 is presence of G and/or C; at position 5535 is presence of A and/or T;
at position 5845 is presence of C and/or T; and at position 6911 is presence of T and/or C.

[0018] In one embodiment of the invention preferably the method for diagnosis described herein is one in which the polymorphism in the P2X₇ protein as defined by the position in SEQ ID NO: 4. is any one of the following: val76ala, his155tyr, val245gly, arg270his, arg276his, ala348thr, thr357ser, pro430arg, ala433val, gln460arg, ser490gly and glu496ala.

[0019] The method for diagnosis is preferably one in which the sequence is determined by a method selected from amplification refractory mutation system, restriction fragment length polymorphism and primer extension.

[0020] The status of the individual may be determined by reference to allelic variation at any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more positions.

[0021] The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation.

[0022] It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant nucleotides at one or more polymorphic positions of the invention. In general, the detection of allelic variation requires a mutation discrimination technique, optionally an amplification reaction and optionally a signal generation system. Table 1 lists a number of mutation detection techniques,

some based on the PCR. These may be used in combination with a number of signal generation systems, a selection of which is listed in Table 2. Further amplification techniques are listed in Table 3. Many current methods for the detection of allelic variation are reviewed by Nollau *et al.*, Clin. Chem. **43**, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

Abbreviations:

[0023]

ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMS™	Amplification refractory mutation system
b-DNA	Branched DNA
bp	base pair
CMC	Chemical mismatch cleavage
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
ELISA	Enzyme Linked Immuno Sorbent Assay
FRET	Fluorescence resonance energy transfer
LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay
NASBA	Nucleic acid sequence based amplification
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SDA	Strand displacement amplification
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication
TGGE	Temperature gradient gel electrophoresis

Table 1 -

Mutation Detection Techniques

General: DNA sequencing, Sequencing by hybridisation

Scanning: PTT*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage

Hybridisation Based

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide arrays (DNA Chips).

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, **14**, 303; WO 95/13399 (Public Health Inst., New York)

Extension Based: ARMS™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, **17**, 2347.

Incorporation Based: Mini-sequencing, APEX

Restriction Enzyme Based: RFLP, Restriction site generating PCR

* Note: not useful for detection of promoter polymorphisms.

Table 1 - (continued)

Mutation Detection Techniques

Ligation Based: OLA

Other: Invader assay

Table 2 -

Signal Generation or Detection Systems

Fluorescence: FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom Patent No. 2228998 (Zeneca Limited)

Other: Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

Table 3 -

Further Amplification Methods

SSR, NASBA, LCR, SDA, b-DNA

Table 4-

Protein variation detection methods

Immunoassay

Immunohistology

Peptide sequencing

[0024] Preferred mutation detection techniques include ARMS™, ALEX™, COPS, Taqman, Molecular Beacons, RFLP, and restriction site based PCR and FRET techniques. Immunoassay techniques are known in the art e.g. A Practical Guide to ELISA by D M Kemeny, Pergamon Press 1991; Principles and Practice of Immunoassay, 2nd edition, C P Price & D J Newman, 1997, published by Stockton Press in USA & Canada and by Macmillan Reference in the United Kingdom. Histological techniques are described in Theory and Practice of Histological Techniques by J D Bancroft & A Stevens, 4th Edition, Churchill Livingstone, 1996. Protein sequencing is described in Laboratory Techniques in Biochemistry and Molecular Biology, Volume 9, Sequencing of Proteins and Peptides, G Allen, 2nd revised edition, Elsevier, 1989. Particularly preferred methods include ARMS™ and RFLP based methods. ARMS™ is an especially preferred method.

[0025] In a further aspect, the diagnostic methods of the invention are used to assess the pharmacogenetics of a drug acting at P2X₇.

[0026] Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels and/or message stability.

[0027] Individuals who carry particular allelic variants of the P2X₇ gene may therefore exhibit differences in their ability to regulate protein biosynthesis under different physiological conditions and will display altered abilities to react to different diseases. In addition, differences arising as a result of allelic variation may have a direct effect on the response of an individual to drug therapy. The diagnostic methods of the invention may be useful both to predict the clinical response to such agents and to determine therapeutic dose.

[0028] In a further aspect, the diagnostic methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to diseases mediated by P2X₇. This may be particularly relevant in the development of hyperlipoproteinemia and cardiovascular disease and the present invention may be used to recognise individuals who are particularly at risk from developing these conditions.

[0029] In a further aspect, the diagnostic methods of the invention are used in the development of new drug therapies which selectively target one or more allelic variants of the P2X₇ gene. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the disease process whilst minimising effects on other variants.

[0030] In a further diagnostic aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes.

[0031] According to another aspect of the present invention there is provided a human P2X₇ gene or its complementary strand comprising a variant allelic polymorphism at one or more of positions defined herein or a fragment thereof

EP 1 199 372 A2

of at least 20 bases comprising at least one novel polymorphism.

[0032] Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

[0033] According to another aspect of the present invention there is provided a polynucleotide comprising at least 20 bases of the human P2X₇ gene and comprising a polymorphism selected from any one of the following:

Region	Polymorphism SEQ ID NO: 1
5'UTR	936 C→A 1012 T→C 1147 A→G 1343 G→A 1476 A→G

Region	Polymorphism SEQ ID NO: 2
exon 2	253 T→C
exon 5	488 G→A 489 C→T
exon 7	760 T→G
exon 8	835 G→A 853 G→A
exon 11	1068 G→A 1096 C→G
exon 12	1315 C→G
exon 13	1324 C→T 1405 A→G 1448 C→T 1494 A→G 1513 A→C 1628 G→T 1772 G→A

Region	Polymorphism SEQ ID NO: 3
intron E	4780 C→T 4845 C→T 4849 A→C
intron F	5021 T→C 5554 (GTTT) _{n=3,4} 5579 G→C 5535 A→T
intron G	5845 C→T 6911 T→C

[0034] According to another aspect of the present invention there is provided a polynucleotide comprising at least 20 bases of the human P2X₇ gene and comprising an allelic variant selected from any one of the following:

Region	Variant SEQ ID NO: 1
5'UTR	936 A 1012 C

(continued)

Region	Variant SEQ ID NO: 1
	1147 G
	1343 A
	1476 G

Region	Variant SEQ ID NO: 2
exon 2	253 C
exon 5	488 A
	489 T
exon 7	760 G
exon 8	835 A
	853 A
exon 11	1068 A
	1096 G
exon 12	1315 G
exon 13	1324 T
	1405 G
	1448 T
	1494 G
	1513 C
	1628 T
	1772 A

Region	Variant SEQ ID NO: 3
intron E	4780 T
	4845 T
	4849 C
intron F	5021 C
	5554 (GTTT) _n , n=4
	5579 C
	5535 T
intron G	5845 T
	6911 C

[0035] According to another aspect of the present invention there is provided a human P2X₇ gene or its complementary strand comprising a polymorphism, preferably corresponding with one or more the positions defined herein or a fragment thereof of at least 20 bases comprising at least one polymorphism.

[0036] Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

[0037] The invention further provides a nucleotide primer which can detect a polymorphism of the invention.

[0038] According to another aspect of the present invention there is provided an allele specific primer capable of detecting a P2X₇ gene polymorphism, preferably at one or more of the positions as defined herein.

[0039] An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between alleles through selective amplification of one allele at a particular sequence position e.g. as used for **ARMS™** assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

[0040] An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof

are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4, 2, or 1 of the remaining nucleotides may be varied without significantly affecting the properties of the primer.

[0041] Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1st Edition. If required the primer(s) may be labelled to facilitate detection.

[0042] According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting a P2X₇ gene polymorphism, preferably at one or more of the positions defined herein.

[0043] The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

[0044] The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the corresponding wild type or variant locus in the gene. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection.

[0045] According to another aspect of the present invention there is provided an allele specific primer or an allele specific oligonucleotide probe capable of detecting a P2X₇ gene polymorphism at one of the positions defined herein.

[0046] According to another aspect of the present invention there is provided a diagnostic kit comprising an allele specific oligonucleotide probe of the invention and/or an allele-specific primer of the invention.

[0047] The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase.

[0048] In another aspect of the invention, the polymorphisms of this invention may be used as genetic markers in linkage studies. This particularly applies to the polymorphisms of relatively high frequency. The P2X₇ gene is on chromosome 12q24 (Buell et al, Receptors and Channels, 1998, 5,347-354). Low frequency polymorphisms may be particularly useful for haplotyping as described below. A haplotype is a set of alleles found at linked polymorphic sites (such as within a gene) on a single (paternal or maternal) chromosome. If recombination within the gene is random, there may be as many as 2ⁿ haplotypes, where 2 is the number of alleles at each SNP and n is the number of SNPs. One approach to identifying mutations or polymorphisms which are correlated with clinical response is to carry out an association study using all the haplotypes that can be identified in the population of interest. The frequency of each haplotype is limited by the frequency of its rarest allele, so that SNPs with low frequency alleles are particularly useful as markers of low frequency haplotypes. As particular mutations or polymorphisms associated with certain clinical features, such as adverse or abnormal events, are likely to be of low frequency within the population, low frequency SNPs may be particularly useful in identifying these mutations (for examples see: Linkage disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. *Ann Hum Genet* (1998) 62:481-90, De Stefano V, Dekou V, Nicaud V, Chasse JF, London J, Stansbie D, Humphries SE, and Gudnason V; and Variation at the von willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. *Blood* (1999) 93:4277-83, Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D).

[0049] According to another aspect of the present invention there is provided a computer readable medium comprising at least one novel sequence of the invention stored on the medium. The computer readable medium may be used, for example, in homology searching, mapping, haplotyping, genotyping or pharmacogenetic analysis.

[0050] According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a drug acting at P2X₇ in which the method comprises:

i) diagnosis of a polymorphism in P2X₇ in the human, which diagnosis preferably comprises determining the sequence at one or more of the following positions:

[0051]

positions 936, 1012, 1147, 1343 and 1476 in the 5'UTR region of the P2X₇ gene as defined by the position in SEQ ID NO: 1;

positions 253, 488, 489, 760, 835, 853, 1068, 1096, 1315, 1324, 1405, 1448, 1494, 1513, 1628 and 1772 in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2; and

positions 4780, 4845, 4849, 5021, 5554, 5579, 5535, 5845 and 6911 in the intron region of the P2X₇ gene as defined by the position in SEQ ID NO: 3; and

positions 76, 155, 245, 270, 276, 348, 357, 430, 433, 460, 490 and 496 in the P2X₇ polypeptide as defined by the position in SEQ ID NO: 4;

and determining the status of the human by reference to polymorphism in P2X₇; and

ii) administering an effective amount of the drug.

[0052] Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which drug or drugs to administer and/or in deciding on the effective amount of the drug or drugs. The term "drug acting at P2X₇" means that drug binding with P2X₇ in humans is an important part of a drug exerting its pharmaceutical effect in man. Compounds which are known to be antagonists of the P2X₇ receptor are described in published PCT application nos. WO 99/29660, WO 99/29661, WO 99/29686, WO 00/61569, WO 00/71529, WO 01/42194, WO 01/44170, WO 01/44213 and WO 01/46200. According to another aspect of the present invention there is provided use of a drug acting at P2X₇ in preparation of a medicament for treating a disease in a human diagnosed as having a polymorphism therein, preferably at one or more of the positions defined herein.

[0053] According to another aspect of the present invention there is provided a pharmaceutical pack comprising P2X₇ drug and instructions for administration of the drug to humans diagnostically tested for a polymorphism therein, preferably at one or more of the positions defined herein.

[0054] According to another aspect of the present invention there is provided an allelic variant of human P2X₇ polypeptide comprising at least one of the following:

- a alanine at position 76 of SEQ ID NO 4;
- a tyrosine at position 155 of SEQ ID NO 4;
- a glycine at position 245 of SEQ ID NO 4;
- a histidine at position 270 of SEQ ID NO 4;
- a histidine at position 276 of SEQ ID NO 4;
- a threonine at position 348 of SEQ ID NO 4;
- a serine at position 357 of SEQ ID NO 4;
- a arginine at position 430 of SEQ ID NO 4;
- a valine at position 433 of SEQ ID NO 4;
- a arginine at position 460 of SEQ ID NO 4;
- a glycine at position 490 of SEQ ID NO 4; and
- a glutamic acid at position 496 of SEQ ID NO 4;

or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises at least one allelic variant.

[0055] Fragments of polypeptide are at least 10 amino acids, more preferably at least 15 amino acids, more preferably at least 20 amino acids.

[0056] According to another aspect of the present invention there is provided an antibody specific for an allelic variant of human P2X₇ polypeptide as described herein.

[0057] Antibodies can be prepared using any suitable method. For example, purified polypeptide may be utilized to prepare specific antibodies. The term "antibodies" is meant to include polyclonal antibodies, monoclonal antibodies, and the various types of antibody constructs such as for example F(ab')₂, Fab and single chain Fv. Antibodies are defined to be specifically binding if they bind the allelic variant of P2X₇ with a K_a of greater than or equal to about 10⁷ M⁻¹. Affinity of binding can be determined using conventional techniques, for example those described by Scatchard et al., *Ann. N.Y. Acad. Sci.*, 51:660 (1949).

[0058] Polyclonal antibodies can be readily generated from a variety of sources, for example, horses, cows, goats, sheep, dogs, chickens, rabbits, mice or rats, using procedures that are well-known in the art. In general, antigen is administered to the host animal typically through parenteral injection. The immunogenicity of antigen may be enhanced through the use of an adjuvant, for example, Freund's complete or incomplete adjuvant. Following booster immunizations, small samples of serum are collected and tested for reactivity to antigen. Examples of various assays useful for such determination include those described in: *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; as well as procedures such as countercurrent immuno-electrophoresis (CIEP), radioimmunoassay, radioimmunoprecipitation, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, and sandwich assays, see U.S. Patent Nos. 4,376,110 and 4,486,530.

[0059] Monoclonal antibodies may be readily prepared using well-known procedures, see for example, the procedures described in U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439 and 4,411,993; *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), (1980).

[0060] The monoclonal antibodies of the invention can be produced using alternative techniques, such as those

described by Altling-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas", *Strategies in Molecular Biology* 3: 1-9 (1990) which is incorporated herein by reference. Similarly, binding partners can be constructed using recombinant DNA techniques to incorporate the variable regions of a gene that encodes a specific binding antibody. Such a technique is described in Larrick et al., *Biotechnology*, 7: 394 (1989).

[0061] Once isolated and purified, the antibodies may be used to detect the presence of antigen in a sample using established assay protocols, see for example "A Practical Guide to EUSA" by D. M. Kemeny, Pergamon Press, Oxford, England.

[0062] According to another aspect of the invention there is provided a diagnostic kit comprising an antibody of the invention.

[0063] According to another aspect of the present invention there is provided a polynucleotide comprising any one of the following twenty six P2X₇ haplotypes:

	1012	489	5579	835	853	1068	1096	1405	1513
	SEQ ID 1	SEQ ID 2	SEQ ID 3	SEQ ID 2	SEQ ID 2	SEQ ID 2	SEQ ID 2	SEQ ID 2	SEQ ID 2
1	T	T	C	G	G	A	G	A	A
2	C	C	G	G	G	G	C	A	A
3	C	C	C	A	G	G	C	A	C
4	C	T	G	G	G	A	C	G	A
5	C	C	G	G	G	A	G	A	A
6	C	C	C	A	G	G	C	A	A
7	T	T	G	G	G	A	C	G	A
8	C	T	C	G	G	G	C	A	A
9	C	C	C	G	G	A	C	A	A
10	C	T	G	G	G	G	C	A	C
11	T	C	G	G	G	A	C	A	A
12	C	T	C	G	G	G	C	A	C
13	T	C	C	G	G	A	C	A	A
14	T	C	C	G	G	G	C	A	C
15	C	T	C	G	G	A	C	A	A
16	T	T	C	G	G	A	C	G	A
17	C	C	G	G	G	A	C	G	A
18	T	C	G	A	A	G	C	A	A
19	C	C	C	G	G	G	G	A	A
20	T	C	C	G	G	G	G	A	A
21	C	T	C	A	G	G	C	A	A
22	C	C	C	G	G	G	C	A	C
23	C	T	G	G	A	A	G	G	A
24	T	T	G	G	G	A	G	G	A
25	C	T	C	G	G	G	G	A	A
26	C	C	C	G	G	G	C	A	A

[0064] According to another aspect of the present invention there is provided a human P2X₇ polypeptide comprising one of the following eighteen combinations of allelic variant determined amino acids based on positions identified in SEQ ID NO: 4:

5

10

15

20

25

	155	270	276	348	357	460	496
1	Y	R	R	T	S	Q	E
2	Y	R	R	T	T	R	E
3	Y	R	R	T	T	Q	E
4	Y	R	R	T	S	R	E
5	Y	R	R	A	T	Q	A
6	Y	R	R	A	T	Q	E
7	Y	R	R	A	S	Q	E
8	Y	R	H	T	S	R	E
9	Y	H	R	A	T	Q	E
10	H	R	R	T	T	Q	E
11	H	R	R	T	T	R	E
12	H	R	R	A	T	Q	A
13	H	R	R	A	S	Q	E
14	H	R	R	A	T	Q	E
15	H	R	R	T	S	Q	E
16	H	H	R	A	T	Q	A
17	H	H	R	A	T	Q	E
18	H	H	H	A	T	Q	E

30

[0065] According to another aspect of the present invention there is provided a polynucleotide which encodes any human P2X₇ polypeptide combination of allelic variants defined herein.

[0066] The invention will now be illustrated but not limited by reference to the following Examples. All temperatures are in degrees Celsius.

35

[0067] In the Examples below, unless otherwise stated, the following methodology and materials have been applied.

[0068] AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable DNA polymerase.

[0069] General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989) or "Current Protocols in Molecular Biology", Volumes 1-3, Edited by F M Ausubel, R Brent & R E Kingston, published by John Wiley, 1998.

40

[0070] Electropherograms were obtained in a standard manner: data was collected by ABI377 data collection software and the wave form generated by ABI Prism sequencing analysis (2.1.2).

Example 1

45

Identification of Polymorphisms

1. Methods

50

DNA Preparation

55

[0071] DNA was prepared from frozen blood samples collected in EDTA following protocol I (Molecular Cloning: A Laboratory Manual, p392, Sambrook, Fritsch and Maniatis, 2nd Edition, Cold Spring Harbor Press, 1989) with the following modifications. The thawed blood was diluted in an equal volume of standard saline citrate instead of phosphate buffered saline to remove lysed red blood cells. Samples were extracted with phenol, then phenol/chloroform and then chloroform rather than with three phenol extractions. The DNA was dissolved in deionised water.

Template Preparation

[0072] Templates were prepared by PCR using the oligonucleotide primers and annealing temperatures set out below. The extension temperature was 72° and denaturation temperature 94°. Generally 50 ng of genomic DNA was used in each reaction and subjected to 35 cycles of PCR. Where described below, the primary fragment was diluted 1/100 and two microlitres were used as template for amplification of secondary fragments. PCR was performed in two stages (primary fragment then secondary fragment) to ensure specific amplification of the desired target sequence.

Polymorphisms in P2X₇

[0073]

Region	Size	Polymorphism	protein change	frequency
5'UTR		936 C→A		3/56
		1012 T→C		42/56
		1147 A→G		3/56
				2/52
		1343 G→A		35/52
		1476 A→G		
exon 1	146bp			
intron A	21.7kb			
exon 2	168bp	253 T→C	val76ala	2/54
intron B	1.1kb			
axon 3	68bp			
intron C	4.7kb			
exon 4	73bp			
intron D	1.5kb			
axon 5	95bp	488 G→A	silent his155tyr	2/54
		489 C→T		17/38
intron E	2.8kb	4780 C→T		39/52
		4845 C→T		39/52
		4849 A→C		28/36
exon 6	80bp			
intron F	617bp	5021 T→C		1/34
		5554 (GTTT) _{n=3,4}		n=3, 14/40
		5579 G→C		26/40
		5535 A→T		1/44
exon 7	129bp	760 T→G	val245gly	1/40
intron G	1.3kb	5845 C→T		2/40
		6911 T→C		33/50
exon 8	136bp	835 G→A	arg270his	16/52
		853 G→A	arg276his	1/54
intron H				
exon 9	91bp			
intron I	1.7kb			
exon 10	64bp			
intron J	84bp			

EP 1 199 372 A2

(continued)

Region	Size	Polymorphism	protein change	frequency
exon 11	149bp	1068 G→A 1096 C→G	ala348thr thr357ser	18/62 5/66
intron K				
exon 12	101bp	1315 C→G	pro430arg, splice site	4/66
intron L	3.8kb			
exon 13	497bp	1324 C→T 1405 A→G 1448 C→T 1494 A→G 1513 A→C 1628 G→T 1772 G→A	ala433val gln460arg silent ser490gly glu496ala silent silent	1/54 3/54 2/54 2/54 8/54 2/52 24/54

Positions in the 5' UTR refer to SEQ ID NO: 1.

Positions in exons refer to SEQ ID NO: 2.

Positions in introns refer to SEQ ID NO: 3.

Positions in protein refer to SEQ ID NO: 4.

[0074] Evidence for effects of some polymorphisms on transcription are as follows. C at position 1012 SEQ ID No 1 disrupts the TCAAT motif from an enhancer binding sequence reported in intron 1 of EGFR. A at position 1147 SEQID No 1 disrupts the reverse sequence of the TCCTGC motif which is also an enhancer binding sequence from intron 1 EGFR. (Maekawa T., Imamoto F., Merlino G. T., Pastan I., Ishii S.

Cooperative Function of Two Separate Enhancers of RT the Human Epidermal Growth Factor Receptor Proto-oncogene J. Biol. Chem. 264:5488-5494 (1989)).

Example 2

Haplotype analysis

a) The following allele frequencies were determined in a Swedish population.

[0075]

SEQ ID NO	Position	Frequency
1	1012	46/60
2	489	27/60
3	5579	39/60
2	835	16/58
2	853	3/60
2	1068	24/58
2	1096	6/58
2	1045	11/60
2	1513	10/60

b) Haplotype data.

[0076] Analysis of 15 Swedish families with at least one asthmatic child using primer extension (SNaPShot™, Perkin

EP 1 199 372 A2

Elmer) genotyping and GeneHunter™ analysis demonstrated the following haplotypes:

	1012	489	5579	835	853	1068	1096	1405	1513	Frequency n/58
1	T	T	C	G	G	A	G	A	A	1
2	C	C	G	G	G	G	C	A	A	3
3	C	C	C	A	G	G	C	A	C	1
4	C	T	G	G	G	A	C	G	A	5
5	C	C	G	G	G	A	G	A	A	1
6	C	C	C	A	G	G	C	A	A	8
7	T	T	G	G	G	A	C	G	A	1
8	C	T	C	G	G	G	C	A	A	3
9	C	C	C	G	G	A	C	A	A	3
10	C	T	G	G	G	G	C	A	C	2
11	T	C	G	G	G	A	C	A	A	2
12	C	T	C	G	G	G	C	A	C	3
13	T	C	C	G	G	A	C	A	A	4
14	T	C	C	G	G	G	C	A	C	1
15	C	T	C	G	G	A	C	A	A	2
16	T	T	C	G	G	A	C	G	A	1
17	C	C	G	G	G	A	C	G	A	2
18	T	C	G	A	A	G	C	A	A	2
19	C	C	C	G	G	G	G	A	A	1
20	T	C	C	G	G	G	G	A	A	1
21	C	T	C	A	G	G	C	A	A	4
22	C	C	C	G	G	G	C	A	C	3
23	C	T	G	G	A	A	G	G	A	1
24	T	T	G	G	G	A	G	G	A	1
25	C	T	C	G	G	G	G	A	A	1
26	C	C	C	G	G	G	C	A	A	1

This results in the following proteins:

position	SEQ ID NO 4	155	270	276	348	357	460	496	Frequency N/58
amino acid		Y	R	R	T	S	Q	E	1
		Y	R	R	T	T	R	E	7
		Y	R	R	T	T	Q	E	2
		Y	R	R	T	S	R	E	1
		Y	R	R	A	T	Q	A	5
		Y	R	R	A	T	Q	E	3
		Y	R	R	A	S	Q	E	1
		Y	R	H	T	S	R	E	1

EP 1 199 372 A2

(continued)

<i>position SEQ ID NO 4</i>	155	270	276	348	357	460	496	Frequency N/58
	Y	H	R	A	T	Q	E	4
	H	R	R	T	T	Q	E	9
	H	R	R	T	T	R	E	2
	H	R	R	A	T	Q	A	4
	H	R	R	A	S	Q	E	3
	H	R	R	A	T	Q	E	3
	H	R	R	T	S	Q	E	1
	H	H	R	A	T	Q	A	1
	H	H	R	A	T	Q	E	8
	H	H	H	A	T	Q	E	2

c) Analysis

[0077] Ben J. Gu, Weiyi Zhang, Rebecca A. Worthington, Ronald Sluyter, Phuong Dao-Ung, Steven Petrou, Julian A. Barden, and James S. Wiley, J. BioL Chem. (2001) 276: 11135-11142 reported that Ala at 496 (C at 1513) leads to loss of function in P2X7. Only one polymorphism was reported since they only analysed the final exon for SNPs

SEQUENCE LISTING

5 <110> AstraZeneca AB
 <120> Chemical Compounds
 <130> morten
 10 <140>
 <141>
 <160> 4
 15 <170> PatentIn Ver. 2.1
 <210> 1
 20 <211> 4900
 <212> DNA
 <213> Homo sapiens
 25 <400> 1
 gactcactat agggagaccg gcagatctga tatcatcgcc actgtggatc cgaattctag 60
 aaggcctatg ttctaagcat caggctttac ctgtgaatct cctcttttta cagatgaaga 120
 tgactgtatc actcagattc ccggcaggaa agcaatggca tactcaagtg gggtaactaa 180
 tgatggaacc atttacaag gtgtggacag agttaagaaa aagcaatagg agatagtga 240
 30 cttcctgggg ctggtaaag tggggagccc ttaccactcc caggactaaa ggaggggagtg 300
 gtgccagaa gccctgccta tatgcaactg agaagggcag ggccaggagg tcacgtccat 360
 cctcactgct ctccagtctc ctgaactgga agccagaagg tgagggggaac cctgatgcag 420
 tttgtatgtg tgagaaagta caattagttt agactgaaaa actgaaaaac taccgggcca 480
 35 cttagcaggc tggaataaca gaaatggatc aagccagctg taaagataac aggggaacaat 540
 aattctctgt agctgtaaag tgataataca accctgcac tttgagtga tgctgaaaca 600
 ttgtccttta aaatcagaga ccttcagaaa cttcgtgtt tgaaattaca tgactaagac 660
 tgaaatattc caattttgcc tggaagattt aagtcactct gacacagaga agcagcctca 720
 atttacaact caggagcaga gcttcagata aagattttct ggacacattt gacatgtatc 780
 40 ttagctatgt tgcttcctag gaaacagggc cctgggtcct ctttgcaatc cagactgaag 840
 ttgactgctt tgtacaaacc tgttttgctt tgagtccatc aaaacatgac ttcatttga 900
 ttttatctca actccacttt cctcggaaac ctatactaaa ttgctgtttt cctttgtttg 960
 gtgatgtgcg tagctcttct ggtgggtggt gtcctcact gaataggta ataaacctaa 1020
 45 ctttgttga ctgccactgt gtcctgggtg atctttggct gattggtcta ggtcatagat 1080
 cgacctgccg ggggtgcagag gaggggtggag agtaactcag aggggtcaagc atgaaagatc 1140
 tggcagaaaa ataaagcccc tccaccccca ccaccttac ccctgcaaat ctgatttccc 1200
 ccaccaactg cagaccagag tattataagg ggcggtggaa gaagaggggg agatcttcat 1260
 50 ttaccagag ctctataca tcaggggctg aataaagggt ttagagaaatg aatgaatcaa 1320
 tctctgagtg gggcttcagg cagtggaaag atctcagtc tttctgagg cataatggaa 1380
 gctcccagtc ttgtgacatt tgcaaggctg cccctttctc ccaagagaca tgagaccaa 1440
 aaagtgaag gaaagggggg aaaagggaga attctaaaaa tgcccatcct ctgaacacca 1500
 55 tctttgtgta ggcactctgg ggaggccagc tgggggtgagg tcatctgcca gccaggcccc 1560
 taggacttgg cgcttcttgt ttatcacagc cacatgtggg gccactgcca gggcccgccc 1620

EP 1 199 372 A2

caactctgca gtcattggag gagcttgaag ttaaagactc ctgctaaaaa ccagtacgtt 1680
 tcatttttga gttactggga gggggcttgc tgtggccctg tcaggaagag tagagctctg 1740
 gtccagctcc ggcagggag ggaggctgtc accatgccgg cctgctgcag ctgcagtgat 1800
 5 gttttccagt atgagacgaa caaagtcact cggatccaga gcatgaatta tggcaccatt 1860
 aagtggttct tccacgtgat catcttttcc tacgttttgt aagtgggac tggggaggac 1920
 ccagatctct gcagtggccg acagcacaga aagccccagc gggcagcttc aggtgcacat 1980
 tctgaatctc acatggtttt cgaatctgag acgtgctctc acagccagct gggcgggagg 2040
 10 gaggaagcag cagcaggcaa gaggaacagg tgccaggctg cagcagagag aagccacagg 2100
 acaagcgga ttcctttctg ctctacttca ggcccgcag ggcgcgaag gcagggcgtg 2160
 cctggggaag gtaggaaagc gcagggaac accctggatc ccaggggagg aggcaggat 2220
 ctcagggcac gcttgggtgat catgctggca tctgagtcac catgcttggg aggaatagga 2280
 ccaggcttga aaatgtgtta taactttagg tctcaccaa cgtcaggaag gccctgctt 2340
 15 ttggtttttg tttcttctaa aagaaactta ctgagatata atttatacac catacaattg 2400
 acccatttaa aggttaccat ttaatgattt tcagattatt ccagagttg tgcaaccatc 2460
 cccacaatca attttagaat attttaactc actcaaaagg aatcccacac tcttcacca 2520
 tcatttccaa cactgttctt cctctctccc acccatcaat ttcctttctg cctctatgga 2580
 20 tttgcgatt ctggacattt catataaatg gaatcacata atatgtggc ctttgggca 2640
 cttagcgtgt tttcaatgct catccatgtt gtagcatgtg ttgatacttc attcaatttt 2700
 tttttttaa gagacgggt ctcactattt tgtccaggct ggtctcaaac tctgggactc 2760
 aagtgatctg cctgcctcgg cctcccaagg tgtcaggatt acaggcgtga gccattgcac 2820
 cggctgata cttcattcct tttacggct gagtagtact ccattgcatg gatagaccac 2880
 25 tttttctat ccattcatcc attgatggac attgggggtg tttctctttt ttgggtatca 2940
 tgaataatgc cacatgaaca tttgtgtaca aggttttatg tggatatata tctccttctc 3000
 tctcgaatat gtacctaaga gtaaaaattg ctaggtcata tgtaactat gtttccactt 3060
 tggggggaat gtggagctga atttcacagc agctgcagtt ttttacattc ctatcagcag 3120
 30 agtatgaggg atccaatttc tccacatcct caccaacgct tgttatcgtc tgtctttttg 3180
 ggttttgtt ttgtcatttt gttttgtct ttgagatgaa gtcttgcctt gttgccagg 3240
 ctggagtga gtggcgcaat ctgggtcac tgcaacctcc acctccccgg tcaagcgat 3300
 tctctgcct cagcctcatg agtagctggg attacagggtg tgcgtacca ctcctcata 3360
 35 atttttgtat ttttagtaga gatgaggttt cgccatgtag gccaggctgg tctcaaaactc 3420
 ctgacctcaa gtatccgcc cacctggcc tcccaaagt ctgggattac aggcattgagc 3480
 cgccacgccc ggctgattgt ctgtcttttt tattatagcc atgctagtgg gtgtgaagt 3540
 gtagttcatt gtggttga tttgaatttc cctgatgggt agtgccctct attctctgtg 3600
 ctgattgata atgatgatga aggcaatttg tatctataga gtggcagtggt agtttactaa 3660
 40 gagttagggt aacttatttc atagtactgg ctatgtcttc tgggccaagt cattaacttc 3720
 tctgagcctc agtttctgca tctgttcata ggttgtggc aattaacca aaaaaaagg 3780
 catgaacagc ccttatcatg atgactgaca taggataaga gctccataac tagtatctat 3840
 ttttaaaaat aatcttttta agtctgggag tgggtggctc cacctgtaat cccaacactt 3900
 45 tgggaggccg aggcgggtgg atcacgaagt caggagtttg agaccagcct ggccaatatg 3960
 gtgaaacccc atctctacta aaaatacaaa aattagtggg gagtgggtgt gcacacctgt 4020
 aatccagct actaggagg ctgaggcagg agaactcgtt gaaccggag gcggagggtg 4080
 cagtgagccg agatcaagcc actgcactcc agcctgggtg acagagcaag actccatctc 4140
 50 aaaataataa taatagtaat aatttttttg attatataat agtatatatg tatataaat 4200
 acatgtatgt atttttatct atatcctctg ctctgacctc caaagtaacc acgtccaagt 4260
 tcaggatttg aaatctggaa acgtggattc aaaaatcctt cactctttg agccttgggt 4320
 tcatcatctg taaaatgggg agaattgttg ataggaatat taaatgaact aataaatgca 4380
 aagctgtttg agaatatat ggcataatgt aatccctgat taagtgttag tcttattat 4440
 55 taataatgct attattagga ttattattat tcgattcata tgtttactgt tcaacaaata 4500

EP 1 199 372 A2

5 ttgaatgata aacatatatg ctgggtccgg catggtggcc catgcctgta attccagcac 4560
 tttgggagggc caaggcgggc aggtcacttg aggtcaagag tttgagacca gcctggccaa 4620
 tgtggtggaa actccatctg tgctaaaaat acaaaaatta gccgggcatg gtggtgggtg 4680
 cctgtaatcc cagctactcg ggaggctgag acaggagaat cacttgaacc caggaggtgg 4740
 aggttgccagt gagccaagat tgcaccactg cactccagcc tgagccacag agcaagactc 4800
 tgtctcaaaa aaaaaaaaaa aaaatatata tatatatata tatatatata gtatttttag 4860
 tagagatggg gttttgccat ctcttatata tttttatatt 4900

10

<210> 2

<211> 1853

<212> DNA

15

<213> Homo sapiens

<400> 2

20

aaaacgcagg gagggaggct gtcaccatgc cggcctgctg cagctgcagt gatgttttcc 60
 agtatgagac gaacaaagtc actcggatcc agagcatgaa ttatggcacc attaatgtgt 120
 tcttccacgt gatcatcttt tctacgtttt gctttgctct ggtgagtgc aagctgtacc 180
 agcggaaaga gcctgtcatc agttctgtgc acaccaaggt gaaggggata gcagaggtga 240
 aagaggagat cgtggagaat ggagtgaaga agttggtgca cagtgtcttt gacaccgcag 300
 actacacctt ccctttgcag gggaactctt tcttcgtgat gacaaacttt ctcaaacag 360
 aaggccaaga gcagcgggtg tgtcccgagt atcccaccgc caggacgctc tgttcctctg 420
 accgagggtg taaaaaggga tggatggacc cgcagagcaa aggaattcag accggaaggt 480
 gtgtagtgc tgaagggaac cagaagacct gtgaagtctc tgctgtgtgc cccatcgagg 540
 cagtgaaga ggccccccgg cctgtctct tgaacagtgc cgaacttct actgtgtc 600
 tcaagaacaa tatcgacttc ccggccaca actacaccac gagaacatc ctgccaggtt 660
 taaacatcac ttgtaccttc cacaagactc agaattcaca gtgtccatt ttccgactag 720
 gagacatctt ccgagaaaca ggcgataatt ttccagatgt ggcaattcag ggcggaataa 780
 tgggcattga gatctactgg gactgcaacc tagaccgttg gttccatcac tgccgtccca 840
 aatacagttt ccgtcgcctt gacgacaaga ccaccaacgt gtcctgttac cctggctaca 900
 acttcagata cgccaagtac tacaaggaaa acaatgttga gaaacggact ctgataaaag 960
 tcttcgggat ccgttttgac atcctggttt ttggcaccgg aggaaaattt gacattatcc 1020
 agctggttgt gtacatcggc tcaacctct cctacttcgg tctggccgct gtgttcacg 1080
 acttctcat cgacacttac tccagtaact gctgtcgtc ccatatttat cctggtgca 1140
 agtctgtca gccctgtgtg gtcaacgaat actactacag gaagaagtgc gattccattg 1200
 tggagccaaa gccgacatta aagtatgtgt cctttgtgga tgaatccac attaggatgg 1260
 tgaaccagca gctactaggg agaagtctgc aagatgtcaa gggccaagaa gtcccaagac 1320
 ctgcgatgga ctacacagat ttgtccaggc tgcccctggc cctccatgac acaccccgca 1380
 ttcctggaca accagaggag atacagctgc ttagaaagga ggcgactcct agatccaggg 1440
 atagccccgt ctggtgccag tgtggaagct gcctccatc tcaactccct gagagccaca 1500
 ggtgctgga ggagctgtgc tgccggaaaa agccgggggc ctgcatcacc acctcagagc 1560
 tgttcaggaa gctggtcctg tccagacacg tcctgcagtt cctcctgtc taccaggagc 1620
 cctgtctggc gctggatgtg gattccacca acagccggct gcggcactgt gcctacaggt 1680
 gctacgccac ctggcgcttc ggctcccagg acatggtgca ctttgccatc ctgccagct 1740
 gctgcgctg gaggatccgg aaagagtttc cgaagagtga agggcagtag agtggcttca 1800
 agagtcccta ctgaagccag gcaccgtggc tcacgtctgt aatccacct ttt 1853

55

<210> 3

<211> 11266

<212> DNA

<213> Homo sapiens

<400> 3

catcacctac aaaggaaacc ccaaateccag tagcagtcac tccccattct ccccttcccc 60
 10 tgccccctggc cacagtctac tttctgtctc tatagatgcc tattctggac atttccctata 120
 aatagaattg tatatggtgt ggccttttgt gtctgtcttc tttcactcag catcatgttc 180
 tccaggcca tccatgttgt agcctgtgtc attgtctcat ccttcttatg gctaaataag 240
 attctgtgta tgaatgtacc acatttttatt tgtccattca tccgtcagtg gccacttgca 300
 tggtttccac ttttttggcg attctgagta gtgctgctat aagcattcgt gtgcacattc 360
 15 tgggtggatat cgaatcactt ctccacatct tagtaacaca cgtcacttac tccccactct 420
 gtcacecttc tatctgcagt atcccaccgg caggacgctc tgttcctctg accgagggtg 480
 taaaaggga tggatggacc cgcagagcaa aggtaccttc tgtttctttt cccgagaccc 540
 taggggtgga tggcttgga tcttggtgac atttgatgat cccaggtcag gtcttcagcc 600
 20 tctgtctca gctgccctct tccaccatca ccaagccata ggcgagtctg cccatgcttc 660
 ggctctgtcc ccagcagacc agctgctgac tgtaaacatg actccagttt tccagtga 720
 gaagaagctc ctaaaacct agcaggttca ggattctaat cggtagaaaa ttcacatggc 780
 ctatagcatc atctgagtat tctaaacttt cccctgaat ttcctcaaag gttgaggacc 840
 atgaactttt acccccaggg gaacctggca gcaataccca tattaacctg cagaattttt 900
 25 tttgtttttt attttatttt attttttaaa cattttttgc actgttttat tttgattttg 960
 attttgattt tatttatatc taagtgcagt gctattgcga tactgcagaa tttctttatc 1020
 tcacatttta acttaaaag gcacagggca gcgagcgagc aggtcgggtg ctgtaatccc 1080
 agcacttttg gaggtgagg cagatggatg cttgaggcca ggggttcgag aacagcctgg 1140
 30 aaaacatggt gaaacccctg ctctactaaa aatacaaaaa tcagccagac atggtggcac 1200
 acgcttataa tcccagctac ttgggaggct gagacgtgag aatcacttga acctggaagg 1260
 cagaggttgc agtgagccaa gatcatgcca ctgcactcca gcatgggtga cagagcgaga 1320
 cccctttaa aaaaaaaaaa aaaggcacag ggcaatttta aaaatactgc aaatagtaaa 1380
 35 aaaaaaaaaa tcagtgggta taatgcaa acacacaaaa aggcataatgc ccattactgc 1440
 attctactcc atactgtatg tgtatttgag ttagtataaa agttatttta acattgtctc 1500
 ctatttaatt aattctccct tggaaactga ttaatcatcc tggcactcca ggaagatgtg 1560
 ccatgctgat ttcattgctt tgcacatcct gggcaggctg tgtaccctt gagggacttg 1620
 tgcccccttg agaggccatg ttctagtcca ttataactaa gtgagagcat acacctgttc 1680
 40 cgctccctc atgggcacct tttcttataa agaaacaaaa gagccagcag aatccacagt 1740
 cttctgtgt tctctctgat ctttattatg tttgtctgt ttgccttgcc ttgtgttcgt 1800
 tgtggttagg atgggcttga tgggaagctga agctgcgtgg gttggaaagc ctggtcaaag 1860
 cctagtctct cggccgggtt gagttaatga tgtccctcct ggagaacgct ctctctgcag 1920
 45 ttctttcaca tctgtggttc tacgatgctt tgacccttat aggaattcag accggaagg 1980
 gtgtagtga tgaagggaac cagaagacct gtgaagtctc tgctggtgc cccatcgagg 2040
 cagtggaaag ggccttgcgg tgagtgcgt ggggagacag acacagtggc cctcagcggc 2100
 gaccagatga ggccttgcgg aggtgcttg ggccttcccc tctcagcaca gccctgcaa 2160
 50 gtctgggtc ctaccggctt ggggacccct gcgtctgga tgcactgctt ggcacaaact 2220
 agtatctctg ggagggccat ggtggttgt aaactgtgt aacactcctg taccaactgg 2280
 taaatagcta ctaccctgag cactcttggg tgcctctggc ccttctctc cccagatct 2340
 tccagggtac cccagaccc cctctgttag tgcacagca ggatccctc tgacttgtca 2400
 gtgtccatc tgagtgtatc aggataggaa ggaaggagg agatggaaag gaaggacgaa 2460
 55 gcgaggaag agaaggga ggggagga aagcaaaagg ggtgagggtt aaaggagg 2520

ggaaaggaag ttttctcaaa ttaaatgctt acaatgacat acagatttgg tggcccttg 2580
 tattgatgct tcgcttcaat acacaaagtc acaatgttaa atctcagaag ccacaagggc 2640
 tgatgtattt cagcagagaa tagttagaaa gacctggatt caattcctag ctctaacc 2700
 5 attttgctgt gtgtccttgg gaaaatggct taacctctct gagtttcagt gtcctcacct 2760
 gtaaaagcag aataataatt tcaccaactt catagggctg ttgtaaggat taaatgagat 2820
 gatacttgta cagttattgt aaggtaagcc ccatgcatgc ctggcttaca cacacacaca 2880
 cacacacaca cacacacag cacacacaca cacacacaca atctaccctt agaagtgtgg 2940
 10 tggttctaga ccagcactgt ccaattgaac ttgatgcagt gatggaaatt tctgtatctg 3000
 tgctgtccaa tagggcagct actaggtaca tgggctatt gactacatga aatgcgacta 3060
 ctgaattttt gaaagagatg atagatgata gatagaaaga tagatagata gataaataga 3120
 tagataatag atagatagac aggtagatag atagatagat agatagatag atagatagat 3180
 agatagagtt ttgctatgtt gccaggctg gttttgaact cctgggctca agcgatcctc 3240
 15 ctgccttggc ctcccaaagt gctgggggta caggtttgag ccattgctcc cagcctgaat 3300
 ttttaattaa atttaaatat aatagccac acatgtctag tggctaccat attggacagc 3360
 gcagttctag accgatgtga ttcaggatca ttccctcagc atcgtggggc aaagagaaaa 3420
 ctgccccaa ctggcctgta gaaggctcag gcgaagggtt cccaatgccg ggatgggggg 3480
 20 tgccgtcagc agcatcacc ctatgatctt tcaatcgcta atagctccac tcaggttcat 3540
 ttctcggtca ggggcatttc ttgggaatc acccagctct gggagataca gcagcctcca 3600
 ctccagtagt cctgttcaa gacaagcggc ccttgactga ctgcagtttc agtccagct 3660
 ctgctatcaa ctactcatt aaataaactg catctccagt gtgctgcct ctgggctgga 3720
 ttttgacgtg acctgggcaa gcaactccct gaacttcagt ttctcatata ttatatgaat 3780
 25 tagctaagat ggttcgttta atcattcatt caacacatcc atcaccacgt agtaggtgtt 3840
 agatatttat ttcatacgt actacgcata agagactttg ctaagtttta ggtaaaatac 3900
 aagtcaccaga tacggagcaa gtctoacca ctgtacatac ctgaatgtgt aattacatca 3960
 ctgtaagagg tgccacagta aatgccactg ggtcttgtgt tagtccattc tcacacaaag 4020
 30 aactacctag ccaggtgcgg tggctcacgc ctgtaatccc aactcttgg caggctgagg 4080
 caggcggatc acttgaggtc aggagtttga taccagcctg gcaaacatgg tgaaacccca 4140
 tctctattaa aaaatgcata aattagccag gtgtgggtgg acacgcctgt aatcctggct 4200
 actcgggagg ctgaggcagg agagtgcctt gaaccgggga gatggagggt gcagtgacc 4260
 35 gagatcgccg cactgcactc cagcctgggt gacagagtga gactccatct cagaaaaaaa 4320
 taaaaataaa aataaagaac tacctgagac caaacacttt acgaaaaaaa agaggtttaa 4380
 ttgactcaca gctccacagg cttaacagga agcctcagga gacttacaat catggcagaa 4440
 ggccaagggg aagcaaacac atcttaccat gatggagcag gaggggggtt tcgggggatg 4500
 40 tgccgcacac ttttaaatga tcagatctcg tgagaactca ctactatca cgagaacagc 4560
 aaggaggaag tccgccccca tgattcagtc acctccacc aggccctcc tctggcacat 4620
 ggggattaca attcaagatg agatttgggt ggggacacag agccaaacca tatcagatct 4680
 caagaaggga gaaattcttc ttggaggagc tggaggggct ttgtggagag ttccagaatg 4740
 ctttgcctac taggtttgct gtatccattt ctcttcagc atcccaaaga ccaagccaa 4800
 45 aaaccagaag cctctggtcc cactggccca tgggctccct cgtcccccac cgtcactaat 4860
 ggccattttg catgtctctc tcccaggcct gctctcttga acagtgcga aaacttcact 4920
 gtgctcatca agaacaatat cgacttcccc ggccacaact acaccacgta agtgccagg 4980
 ctgctcggct gtcttagtta tctactgctg agtaataaat tatcccaaac ctccagaagcc 5040
 tgaaacaaca aacgcctatt gtctccacg gttctgtgg gtcaggaatc tgggaatgac 5100
 50 tttgctgcgt ggttctggct caaggtctgt caggtttagt ccaagctgtc aaccagggct 5160
 gcagtcattt ctaggcttga ctggggctgg agaaccctt tccaagctct cacacagttg 5220
 ctctggggag agctcagttc ctaccacgt gaacctcgc ctagaccact tgagtatcct 5280
 tggatatatg tggtggctt ctcccagagc aagtgacca agagagacag agcaagcaac 5340
 55 caagagtata accaagatgg aagccacagt ctttgggggg agacccaac acttctgcca 5400

EP 1 199 372 A2

tatgccattg gtcacacaga tcaacctg tccagtgtga gagggcactg cccagggggtc 5460
 ccaggaggca gggatcattt ggggctttca tggaacctct ccaccacact ggctcactcc 5520
 tgggaaagag acagatctgt tttcaatcga gatgtttgtt tgtttgcttt taattatgga 5580
 5 caggagaaac atcctgccag gtttaaacat cacttgtacc ttccacaaga ctcaaatcc 5640
 acagtgtccc attttccgac taggagacat cttccgagaa acaggcgata attttccaga 5700
 tgtggcaatt caggttggtg gtgctttgta cactgggatg tggggctgtg tgtctagggg 5760
 tggaggatgt caaacagcca agaggccggg cactgggtc ttcataatgt ggctcacatt 5820
 10 tactgagcat ttagtaaatc caccgcgtgc gctaagggtc ttacctacgc tacctcgtca 5880
 aatcccaaaa caatccttat gagttagagc tacttggtgt attcctttcc tgtggctgct 5940
 gtagcaagtt atcaaagctt agtggcttca aacaacacat atttgcttat gttgccagag 6000
 atcagaagtt ggagatgatt ttccctgagc caggggcgtg ctccctctgg gactttaagg 6060
 gagaatccag ttccctcagct tttccacctt ctggagctgc attccttgca tttcttcaaa 6120
 15 gccagcagca taacatcttg cctcagtggc cactttcact ccctatcctg tgtccaatct 6180
 ccctttgcct ctgtcttaaa aagagagaga gcatttataa gagggggcat ttaaggacca 6240
 actggataat ccaggataat ctcccatctc aagatccttc atttaggctg ggcacgggtg 6300
 ctcatgcctg taatcccagc actttgggag gctgagggtg gtggatcacc tgaggtcagg 6360
 20 agttcaacac cagcctggcc aacatggtga aagcccatct ttactaaaaa taaaaaaa 6420
 aaaaaaaat agccgggcat gattgcgggc tctgtaatc ccagctactc gggaggctga 6480
 gacaggagaa tcgcttgaa ctgggaggca gaggttgca tgagccgaga tcgcaccact 6540
 gcaatccagc ctagggtgaca agagcgaaac tccatctcaa aaaaaaaaaa aaaatccttc 6600
 atgtattcgc atctgcaaag agctttccct aggggagtag taggaggtaa agcagaaaag 6660
 25 atatttgata gagtgcctcg aattccagtc taataagttt ggacttgatc tttaatgggg 6720
 gcgtgggggg cattaaaggt gtttgggtac aggagtggtc tgttgaaagt tgtattttag 6780
 gacaatgagt ttaacagtga tgtgtccag acgggggtag ggagagtga gagatgcgat 6840
 tgtggtgcc acaataacac ttgtgcgagt taggtggggc tgtacatatg gttcttcaat 6900
 30 cagcattttt tctctaaaaa ccttaagcaa tctggctat gcaggagat gtctggcgtg 6960
 tgcgtaaact acaccagca gccatagaga ctgtcccttg ttgatccttc agggcggaat 7020
 aatgggcatt gagatctact gggactgcaa cctagaccgt tggttccatc actgccgtcc 7080
 caaatacagt ttccgtcgcc ttgacgaca gaccaccaac gtgtccttgt accctggcta 7140
 35 caacttcagg taactccaag gcccagggtca aactcaccca gtggctgaat cgcattccca 7200
 ggaactggtg agactaattt tggtttccaa ggcaacaaga tgaatgaaa aagactttct 7260
 ctaagaacta ggtgataact gaattttttc cataattttt taaaattctc aaaagagata 7320
 cactctttat tttttactta tttttttttt tttgaaatgg agtctcactc tgtcaccag 7380
 gctgaagtgc agtggcgcca tctcagtcac tgcaaaactc cgcctcccag gttcaagcga 7440
 40 ctctcctgcc tcagcctccc aagtagctga gattacaggc ggatgcacac tgtttataaa 7500
 acaaaactat tgggaaacag aaaagcatag agggggatca aaatcgcca taattccct 7560
 accctgaaat aatcaataac aaccctcggg ggaattttcc tcatctgtac caattatttc 7620
 atacagctcc tatgagatca tagcatatat atatataat cttgtggtat tctgcagggt 7680
 45 ttttcatacc acagccactc aaaattcttt gtaacctca cattaatgat cataacattc 7740
 cattttgtag gtgaacaaat aacaactgct acaattcagg aagtgttttc tttcttttc 7800
 tttcttttc tttttttttt ttagatggag tcacactctg cttgccagg ctggagtga 7860
 gtggcatgat ctcagctcac tgcaacctct gcctcctagg tccaagcgat cctccacct 7920
 50 cccaagtttc tgggaccaca ggcatgtgcc accacaccca gctaattttt gtatattcag 7980
 tagagatggg gtttactgt gttggccagt ctggtctcga actcttgacc tcaagtga 8040
 ttccacacct ggttcccaa agtgctagga ttacagtcat gagccactgt gcctggccca 8100
 aggaggggtt tccatatacc aagcactccc catcgccatc cctaaatctc ccaacaaccc 8160
 tggaaggag atattgttcc tggaagatga tttgcccaag acccacagct gatagtacat 8220
 55 gtttgcataa ttctaacca cgttactctc gacccacac tcacactccc atcccttccc 8280

5 ttcccatctc aatgattttc tcaccgtacg cctccatgaa ttgaatattt gagttgcttc 8340
 ccagtttttc tagtacaagt aaccacagtg tgcattcttg caccgtaaac ttcttctttg 8400
 aattccaggg ttacttccct aggataaatt tcctagactt attgaatcaa aggttggtgaa 8460
 10 cattttatca tatgcttttt atttttaaaa atatctatgg ttataatgtt tcattttttt 8520
 ttctgagaca gagtctcact ctgtcaccca gggttgagtg gaccgggtgc aattatagct 8580
 cactgcaacc tctgctccc aggccaagt gatectccca cctcagctc ctgagtagct 8640
 aggactacag gtgcatgcca ccatgccag ctaattttta aaattttttt gtagagtcgg 8700
 15 ggtctcacta tattgccag gctggtctca aactcctggc tcaagcaatc cgctgcctt 8760
 ggctcctaa agcgttgga ttgcaggtgt gagctactgc acctggccta taattttcat 8820
 ttctaggatt ttatttgggt gctttttcaa agtcatctat tattgttcca gtgagtccca 8880
 ttcttacctt aaggatccta ctctctctgt ccattctact gtatcattcc ttccataccg 8940
 acctattatc tgaagtaact tgggtgggag ttctcctcgt gggctttgaa atactgtctt 9000
 20 cagtagaaaa gatcttatgc aaagtctgc atgtgctgtg tggtatggag tattccttat 9060
 atattactca aagcagcttc atgaactggc aggagccccc ttaaatgtgt ttctgtttct 9120
 gtttttttgt tttttgtct gcatgatgtt ttaaaacttg agacaggcca ggtgcggtgg 9180
 cttatgcctg taatccagc actttgggag gccaaagggtg gaggatcact tgaaccggg 9240
 25 ggtttgaggg tagcctgggc aacatagggg gaccccatct ctacaataa taatttttaa 9300
 aacatcagcc aggtgtgggg gcatgcacct ctggtccag ctactcagga ggctgaggca 9360
 ggaggattgc ttgaacctgg gaggttgagg ctgcagttaa ccgtggttgt gccactgcac 9420
 tccagcctgg gtgacagagt gagaccctta catggtggcc actggctgga gctgagtac 9480
 agtggctcta tttagaaagg ggctgggctt tctgggtcat cactgtcccc gcgctcctt 9540
 30 agtgcttata cctggccac atcactcatt tctgtcatct gcctggcccc tgtgtagaca 9600
 tttgagtttg aaaccttga ctcaaaggca ggctgatgct ttttgettcc tctggatcaa 9660
 tgggaattca tccaaggcaa tggaa'cagc tcctaattgt gataactttt tgatcatccc 9720
 ctgccactgt gctgaatagg cttatggcca ttaagaagag aggacaggat gaatggctcc 9780
 35 ctgactgact gccctccag ggtgttttt tagctgtcag cagaagcatg cggggcagtg 9840
 tacciaatcag gtgtcagcaa gtgtcctcc agcgactgag ttgagcaca aaacatctgc 9900
 tcctggagag acctgagccc tctgaaggcc tcagccagtt atgatgttaa tgttctttta 9960
 gaacaaagtg gtacacccat ttgtgtctg gaatgagcac cagaacaaat ctttggccaa 10020
 40 aaataaattg ttgagggccg ggagcagtg cttatgcctg taatcccaac actttgggag 10080
 gccgaagcag gaggatcacc tgaggtcagg agttcgagac cagcctggcc aacatgggtga 10140
 aacctgtct ctctaaaaa taaaaaatt agctggacgt ggtgacaggt gcctgtaata 10200
 cagctactgg gaggtgagg caggagaaac tgcttgaacc cggaagggtg aggttgagct 10260
 45 gagccggggt catgccactt cactccagcc tgggcaacag agcaaagctc tgtctttaa 10320
 aacaacttaa ataaataat aaattgttga ggtctgatga gtaagtggac aagttatttt 10380
 ccagcagaca cacaaaagag aaggaaatta caggttatag gaggtatttc agaaaatata 10440
 actttctaaa acataggaag ttgaagaagt tgatcacatt acagaattct gttgtttaga 10500
 50 aaatgacctg tggcgaaatg tccttattca gtgaataggt gattccgctt atgcacgacc 10560
 tgtgtgaagt ggatcaggcc acccagaatg cacgatgcgc ttctcaggcc cagcaggagt 10620
 atgtgtctgt gttaatttcc tgtggctatt atgactaatt gccacaaatg tgggtggctta 10680
 aaacaacaga aattaatctt cttatagttc tggagccag aagtttgaa tcaagatgct 10740
 agcagggcca cactcgetct gatgctctac gggaggggtcc tctcttgct cttccagct 10800
 55 ctggtggctc caggcattcc ataactttat agcagcgtcc cacaaatctc tgctccatc 10860
 ctacatggc cttctccact gtgtctctat gtcttcaatc tctttttttt tttttttttt 10920
 ttgaggcagg gtttcactcc agtctcctag actgaagtgc aatggcgtaa tttcgggtca 10980
 ctgcaacctc tgctcccg gctcaagca ttgatctct cttttattct ataaagatac 11040
 tagtcattgg atttgggct taccctaaat ccaggataat ctcatcttga gatgtttaac 11100
 ttaattatat ctgcaaacac tgtatttcca aataaggtca tatcacagcc actagggtt 11160

EP 1 199 372 A2

agatacttga acatatctta tttgggggct caacccttc cagtgtacga aaaacactct 11220
tggtcaaggc ccgatgttcc tcagggcata gccactgac tacctg 11266

5

<210> 4

<211> 595

<212> PRT

<213> Homo sapiens

10

<400> 4

Met Pro Ala Cys Cys Ser Cys Ser Asp Val Phe Gln Tyr Glu Thr Asn
1 5 10 15

15

Lys Val Thr Arg Ile Gln Ser Met Asn Tyr Gly Thr Ile Lys Trp Phe
20 25 30

20

Phe His Val Ile Ile Phe Ser Tyr Val Cys Phe Ala Leu Val Ser Asp
35 40 45

Lys Leu Tyr Gln Arg Lys Glu Pro Val Ile Ser Ser Val His Thr Lys
50 55 60

25

Val Lys Gly Ile Ala Glu Val Lys-Glu Glu Ile Val Glu Asn Gly Val
65 70 75 80

30

Lys Lys Leu Val His Ser Val Phe Asp Thr Ala Asp Tyr Thr Phe Pro
85 90 95

Leu Gln Gly Asn Ser Phe Phe Val Met Thr Asn Phe Leu Lys Thr Glu
100 105 110

35

Gly Gln Glu Gln Arg Leu Cys Pro Glu Tyr Pro Thr Arg Arg Thr Leu
115 120 125

40

Cys Ser Ser Asp Arg Gly Cys Lys Lys Gly Trp Met Asp Pro Gln Ser
130 135 140

Lys Gly Ile Gln Thr Gly Arg Cys Val Val His Glu Gly Asn Gln Lys
145 150 155 160

45

Thr Cys Glu Val Ser Ala Trp Cys Pro Ile Glu Ala Val Glu Glu Ala
165 170 175

50

Pro Arg Pro Ala Leu Leu Asn Ser Ala Glu Asn Phe Thr Val Leu Ile
180 185 190

Lys Asn Asn Ile Asp Phe Pro Gly His Asn Tyr Thr Thr Arg Asn Ile
195 200 205

55

EP 1 199 372 A2

Leu Pro Gly Leu Asn Ile Thr Cys Thr Phe His Lys Thr Gln Asn Pro
 210 215 220
 5 Gln Cys Pro Ile Phe Arg Leu Gly Asp Ile Phe Arg Glu Thr Gly Asp
 225 230 235 240
 Asn Phe Ser Asp Val Ala Ile Gln Gly Gly Ile Met Gly Ile Glu Ile
 245 250 255
 10 Tyr Trp Asp Cys Asn Leu Asp Arg Trp Phe His His Cys Arg Pro Lys
 260 265 270
 Tyr Ser Phe Arg Arg Leu Asp Asp Lys Thr Thr Asn Val Ser Leu Tyr
 275 280 285
 15 Pro Gly Tyr Asn Phe Arg Tyr Ala Lys Tyr Tyr Lys Glu Asn Asn Val
 290 295 300
 20 Glu Lys Arg Thr Leu Ile Lys Val Phe Gly Ile Arg Phe Asp Ile Leu
 305 310 315 320
 25 Val Phe Gly Thr Gly Gly Lys Phe Asp Ile Ile Gln Leu Val Val Tyr
 325 330 335
 Ile Gly Ser Thr Leu Ser Tyr Phe Gly Leu Ala Ala Val Phe Ile Asp
 340 345 350
 30 Phe Leu Ile Asp Thr Tyr Ser Ser Asn Cys Cys Arg Ser His Ile Tyr
 355 360 365
 35 Pro Trp Cys Lys Cys Cys Gln Pro Cys Val Val Asn Glu Tyr Tyr Tyr
 370 375 380
 Arg Lys Lys Cys Glu Ser Ile Val Glu Pro Lys Pro Thr Leu Lys Tyr
 385 390 395 400
 40 Val Ser Phe Val Asp Glu Ser His Ile Arg Met Val Asn Gln Gln Leu
 405 410 415
 45 Leu Gly Arg Ser Leu Gln Asp Val Lys Gly Gln Glu Val Pro Arg Pro
 420 425 430
 Ala Met Asp Phe Thr Asp Leu Ser Arg Leu Pro Leu Ala Leu His Asp
 435 440 445
 50 Thr Pro Pro Ile Pro Gly Gln Pro Glu Glu Ile Gln Leu Leu Arg Lys
 450 455 460
 55

EP 1 199 372 A2

Glu Ala Thr Pro Arg Ser Arg Asp Ser Pro Val Trp Cys Gln Cys Gly
 465 470 475 480
 5 Ser Cys Leu Pro Ser Gln Leu Pro Glu Ser His Arg Cys Leu Glu Glu
 485 490 495
 10 Leu Cys Cys Arg Lys Lys Pro Gly Ala Cys Ile Thr Thr Ser Glu Leu
 500 505 510
 Phe Arg Lys Leu Val Leu Ser Arg His Val Leu Gln Phe Leu Leu Leu
 515 520 525
 15 Tyr Gln Glu Pro Leu Leu Ala Leu Asp Val Asp Ser Thr Asn Ser Arg
 530 535 540
 20 Leu Arg His Cys Ala Tyr Arg Cys Tyr Ala Thr Trp Arg Phe Gly Ser
 545 550 555 560
 Gln Asp Met Ala Asp Phe Ala Ile Leu Pro Ser Cys Cys Arg Trp Arg
 25 565 570 575
 Ile Arg Lys Glu Phe Pro Lys Ser Glu Gly Gln Tyr Ser Gly Phe Lys
 580 585 590
 30 Ser Pro Tyr
 595

Claims

1. A method for the diagnosis of a polymorphism in P2X₇ in a human, which method comprises determining the sequence of the human at one or more of the following positions:

positions 936, 1012, 1147, 1343 and 1476 in the 5'UTR region of the P2X₇ gene as defined by the position in SEQ ID NO: 1;

positions 253, 488, 489, 760, 835, 853, 1068, 1096, 1315, 1324, 1405, 1448, 1494, 1513, 1628 and 1772 in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2; and

positions 4780, 4845, 4849, 5021, 5554, 5579, 5535, 5845 and 6911 in the intron region of the P2X₇ gene as defined by the position in SEQ ID NO: 3;

positions 76, 155, 245, 270, 276, 348, 357, 430, 433, 460, 490 and 496 in the P2X₇ polypeptide as defined by the position in SEQ ID NO: 4;

and determining the status of the human by reference to polymorphism in P2X₇.

2. Use of a diagnostic method as defined in claim 1 to assess the pharmacogenetics of a drug acting at P2X₇.
3. A polynucleotide comprising at least 20 bases of the human P2X₇ gene and comprising an allelic variant selected from any one of the following:

Region	Variant SEQ ID NO: 1
5'UTR	936 A
	1012 C
	1147 G
	1343 A
	1476 G

Region	Variant SEQ ID NO: 2
exon 2	253 C
exon 5	488 A
	489 T
exon 7	760 G
exon 8	835 A
	853 A
exon 11	1068 A
	1096 G
exon 12	1315 G
exon 13	1324 T
	1405 G
	1448 T
	1494 G
	1513 C
	1628 T
	1772 A

Region	Variant SEQ ID NO: 3
intron E	4780 T
	4845 T
	4849 C
intron F	5021 C
	5554 (GTTT) _n , n=4
	5579 C
	5535 T
intron G	5845 T
	6911 C

4. A nucleotide primer which can detect a polymorphism as defined in claim 1.
5. An allele specific primer capable of detecting a P2X₇ gene polymorphism as defined in claim 1.
6. An allele-specific oligonucleotide probe capable of detecting a P2X₇ gene polymorphism as defined in claim 1.
7. Use of a P2X₇ gene polymorphism as defined in claim 1 as a genetic marker in a linkage study.
8. A method of treating a human in need of treatment with a drug acting at P2X₇ in which the method comprises:
 - i) diagnosis of a polymorphism in P2X₇ in the human, which diagnosis preferably comprises determining the

sequence at one or more of the following positions:

positions 936, 1012, 1147, 1343 and 1476 in the 5'UTR region of the P2X₇ gene as defined by the position in SEQ ID NO: 1;

positions 253, 488, 489, 760, 835, 853, 1068, 1096, 1315, 1324, 1405, 1448, 1494, 1513, 1628 and 1772 in the coding region of the P2X₇ gene as defined by the position in SEQ ID NO: 2; and

positions 4780, 4845, 4849, 5021, 5554, 5579, 5535, 5845 and 6911 in the intron region of the P2X₇ gene as defined by the position in SEQ ID NO: 3; and

positions 76, 155, 245, 270, 276, 348, 357, 430, 433, 460, 490 and 496 in the P2X₇ polypeptide as defined by the position in SEQ ID NO: 4;

and determining the status of the human by reference to polymorphism in P2X₇; and

ii) administering an effective amount of the drug.

9. An allelic variant of human P2X₇ polypeptide comprising at least one of the following:

a alanine at position 76 of SEQ ID NO 4;

a tyrosine at position 155 of SEQ ID NO 4;

a glycine at position 245 of SEQ ID NO 4;

a histidine at position 270 of SEQ ID NO 4;

a histidine at position 276 of SEQ ID NO 4;

a threonine at position 348 of SEQ ID NO 4;

a serine at position 357 of SEQ ID NO 4;

a arginine at position 430 of SEQ ID NO 4;

a valine at position 433 of SEQ ID NO 4;

a arginine at position 460 of SEQ ID NO 4;

a glycine at position 490 of SEQ ID NO 4; and

a glutamic acid at position 496 of SEQ ID NO 4;

or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises at least one allelic variant.

10. An antibody specific for an allelic variant of human P2X₇ polypeptide as defined in claim 9.

11. A polynucleotide comprising any one of the following twenty six P2X₇ haplotypes:

	1012	489	5579	835	853	1068	1096	1405	1513
	SEQ ID 1	SEQ ID 2	SEQ ID 3	SEQ ID 2	SEQ ID 2	SEQ ID 2	SEQ ID 2	SEQ ID 2	SEQ ID 2
1	T	T	C	G	G	A	G	A	A
2	C	C	G	G	G	G	C	A	A
3	C	C	C	A	G	G	C	A	C
4	C	T	G	G	G	A	C	G	A
5	C	C	G	G	G	A	G	A	A
6	C	C	C	A	G	G	C	A	A
7	T	T	G	G	G	A	C	G	A
8	C	T	C	G	G	G	C	A	A
9	C	C	C	G	G	A	C	A	A
10	C	T	G	G	G	G	C	A	C
11	T	C	G	G	G	A	C	A	A
12	C	T	C	G	G	G	C	A	C

EP 1 199 372 A2

(continued)

	1012	489	5579	835	853	1068	1096	1405	1513
	SEQ ID 1	SEQ ID 2	SEQ ID 3	SEQ ID 2	SEQ ID 2	SEQ ID 2	SEQ ID 2	SEQ ID 2	SEQ ID 2
5									
	13	T	C	C	G	G	A	C	A
	14	T	C	C	G	G	G	C	A
10	15	C	T	C	G	G	A	C	A
	16	T	T	C	G	G	A	C	G
	17	C	C	G	G	G	A	C	G
	18	T	C	G	A	A	G	C	A
15	19	C	C	C	G	G	G	G	A
	20	T	C	C	G	G	G	G	A
	21	C	T	C	A	G	G	C	A
20	22	C	C	C	G	G	G	C	A
	23	C	T	G	G	A	A	G	G
	24	T	T	G	G	G	A	G	A
	25	C	T	C	G	G	G	G	A
25	26	C	C	C	G	G	G	C	A

12. A human P2X₇ polypeptide comprising one of the following eighteen combinations of allelic variant determined amino acids based on positions identified in SEQ ID NO: 4:

		155	270	276	348	357	460	496
30	1	Y	R	R	T	S	Q	E
	2	YR		R	T	T	R	E
35	3	Y	R	R	T	T	Q	E
	4	Y	R	R	T	S	R	E
	5	Y	R	R	A	T	Q	A
	6	Y	R	R	A	T	Q	E
40	7	Y	R	R	A	S	Q	E
	8	Y	R	H	T	S	R	E
	9	Y	H	R	A	T	Q	E
45	10	H	R	R	T	T	Q	E
	11	H	R	R	T	T	R	E
	12	H	R	R	A	T	Q	A
	13	H	R	R	A	S	Q	E
50	14	H	R	R	A	T	Q	E
	15	H	R	R	T	S	Q	E
	16	H	H	R	A	T	Q	A
	17	H	H	R	A	T	Q	E
55	18	H	H	H	A	T	Q	E

13. A polynucleotide which encodes any human P2X₇ polypeptide as defined in claim 12.

5

10

15

20

25

30

35

40

45

50

55

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 199 372 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
12.05.2004 Bulletin 2004/20

(51) Int Cl.⁷: **C12Q 1/68, C07K 16/28,
C07K 14/705, C12N 15/12**

(43) Date of publication A2:
24.04.2002 Bulletin 2002/17

(21) Application number: **01308837.2**

(22) Date of filing: **17.10.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **21.10.2000 GB 0025859
06.04.2001 GB 0108654
02.11.2000 US 244897 P**

(71) Applicant: **AstraZeneca AB
151 85 Södertälje (SE)**

(72) Inventor: **Morten, John Edward Norris
Cheshire SK10 4TG (GB)**

(74) Representative: **Giles, Allen Frank et al
AstraZeneca,
Global Intellectual Property Patents,
Mereside,
Alderley Park
Macclesfield, Cheshire SK10 4TG (GB)**

(54) **Polymorphisms in the human P2X₇ gene**

(57) This invention relates to polymorphisms in the human P2X₇ gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic var-

iation in the P2X₇ gene, and to the use of P2X₇ polymorphism in treatment of diseases with P2X₇ drugs.

EP 1 199 372 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 01 30 8837

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 97 40462 A (SPECTRA BIOMEDICAL INC) 30 October 1997 (1997-10-30) * abstract; claim 1 *	1-7	C12Q1/68C07K16/2 8 C12Q1/68
X	HALUSHKA M K ET AL: "Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis." NATURE GENETICS. UNITED STATES JUL 1999, vol. 22, no. 3, July 1999 (1999-07), pages 239-247, XP000985696 ISSN: 1061-4036 * page 239 *	1-7	
X	BROOKES A J: "The essence of SNPs." GENE. NETHERLANDS 8 JUL 1999, vol. 234, no. 2, 8 July 1999 (1999-07-08), pages 177-186, XP004173090 ISSN: 0378-1119 * the whole document *	1-7	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12Q
<p>INCOMPLETE SEARCH</p> <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
MUNICH		12 March 2004	Costa Roldán, N
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (P04C07)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 01 30 8837

Claim(s) searched completely:
1-7,9-13

Claim(s) searched incompletely:
8

Reason for the limitation of the search (non-patentable invention(s)):

Article 52 (4) EPC - Method for treatment of the human or animal body by therapy

Further limitation of the search

Claim(s) searched completely:
1-3,5-7,9-13

Claim(s) searched incompletely:
4

Claim(s) not searched:
8

Reason for the limitation of the search:

Claim 4 is directed to a primer, which is defined only in terms of a result to be achieved, i.e. to detect a polymorphism. Thus, such a primer could derive from practically any genomic portion upstream of the polymorphism. Therefore, said claim is unclear (Art. 84 EPC) and has been searched only in so far as it relates to primers of 17 to 50 nucleotides in length which are complementary or identical to portions of the P2X7 gene.

Claim 8 was not searched because it is directed to a method of treatment using a drug acting at P2X7 gene, but the application does not identify any such drugs therefore claim 8 lacks clarity (Art. 84EPC) to the extent that no search is possible.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 30 8837

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	US 6 133 434 A (BUELL GARY NUTTER ET AL) 17 October 2000 (2000-10-17)	4,9	
A	* column 35 - column 38; claim 7 * * column 37 - column 40; claim 1 *	1-3,5-7, 10-13	
D,X	BUELL G N ET AL: "Gene structure and chromosomal localization of the human P2X7 receptor." RECEPTORS & CHANNELS. SWITZERLAND 1998, vol. 5, no. 6, 1998, pages 347-354, XP009021403 ISSN: 1060-6823	4	
A	* the whole document *	1-3,5-7, 9-13	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
D,A	WO 99 29660 A (ASTRA PHARMA PROD ;CLADINGBOEL DAVID (GB); MORTIMORE MICHAEL (GB);) 17 June 1999 (1999-06-17) * abstract *	1-7,9-13	
A	LYNCH K J ET AL: "MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF HUMAN P2X2 RECEPTORS" MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 56, no. 6, December 1999 (1999-12), pages 1171-1181, XP000876836 ISSN: 0026-895X * page 1171 *	1-7,9-13	

	-/-		



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 30 8837

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P,X	WILEY J S ET AL: "GENETIC POLYMORPHISMS OF THE HUMAN P2X7 RECEPTOR AND RELATIONSHIP TO FUNCTION" DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 53, no. 2/3, June 2001 (2001-06), pages 72-76, XP001119468 ISSN: 0272-4391 * page 72; table 1 *	1-7,9-13	
P,X	GU BEN J ET AL: "A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 14, 6 April 2001 (2001-04-06), pages 11135-11142, XP002263729 ISSN: 0021-9258 * the whole document *	1-7,9-13	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)

EPO FORM 1503 03.02 (P04C10)



European Patent
Office

Application Number
EP 01 30 8837

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☒ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
1-13 (all partially), inventions 1 and 28
- ☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number
EP 01 30 8837

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

Inventions 1: claims 1-8 (partially)

Invention 1

A polynucleotide comprising at least 20 bases of the human P2X7 gene comprising the allelic variant 936 A, the use of said polymorphism as a genetic marker in a linkage study, probes and primers for the detection of said polymorphism; and a method for the diagnosis of said polymorphism for determining the status of a human.

Invention 2-16: claims 1-8 (partially)

Inventions 2 to 16

ibid for SNPs at nucleotide positions 1147, 1343, 1476, 488, 1448, 1628, 1772, 4780, 4845, 4849, 5021, 5554, 5535, 5845, 6911.

Inventions 17-21: claims 1-10 (partially)

Invention 17

A polynucleotide comprising at least 20 bases of the human P2X7 gene comprising the allelic variant 253 C, an allelic variant of human P2X7 polypeptide comprising an Alanine at position 76 of SEQ ID NO:4, the use of said polymorphism as a genetic marker in a linkage study, probes and primers for the detection of said polymorphism; and a method for the diagnosis of said polymorphism for determining the status of a human.

Inventions 18 to 21

ibid for SNPs at nucleotide positions:

760 (the allelic variant of human P2X7 polypeptide comprising a Glycine at position 245 of SEQ ID NO:4),

1315 (the allelic variant of human P2X7 polypeptide comprising an Arginine at position 430 of SEQ ID NO:4),

1324 (the allelic variant of human P2X7 polypeptide comprising a Valine at position 433 of SEQ ID NO:4),

1494 (the allelic variant of human P2X7 polypeptide comprising a Glycine at position 490 of SEQ ID NO:4)



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number

EP 01 30 8837

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

Inventions 22-28: claims 1-13 (partially)

Invention 22

A polynucleotide comprising at least 20 bases of the human P2X7 gene comprising the allelic variant 489 T; an allelic variant of human P2X7 polypeptide comprising an Tyrosine at position 155 of SEQ ID NO:4; the polynucleotide which encodes said polypeptides; the use of said polymorphism as a genetic marker in a linkage study, probes and primers for the detection of said polymorphism; and a method for the diagnosis of said polymorphism for determining the status of a human.

Invention 23 to 28

ibid for SNPs at nucleotide positions:

835 (the allelic variant comprising a Histidine at position 270 of SEQ ID NO:4),

853 (the allelic variant comprising a Histidine at position 276 of SEQ ID NO:4)

1068 (the allelic variant comprising a Threonine at position 348 of SEQ ID NO:4)

1096 (the allelic variant comprising a Serine at position 357 of SEQ ID NO:4)

1405 (the allelic variant comprising Arginine at position 460 of SEQ ID NO:4)

1513 (the allelic variant comprising a Glutamic acid at position 496 of SEQ ID NO:4)

Inventions 29-30 : claims 1-8 and 11 (partially)

Invention 29

A polynucleotide comprising at least 20 bases of the human P2X7 gene comprising the allelic variant 1012 C; the use of said polymorphism as a genetic marker in a linkage study, probes and primers for the detection of said polymorphism; and a method for the diagnosis of said polymorphism for determining the status of a human.



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET 8

Application Number

EP 01 30 8837

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

Invention 30

A polynucleotide comprising at least 20 bases of the human P2X7 gene comprising the allelic variant 5579 C; the use of said polymorphism as a genetic marker in a linkage study, probes and primers for the detection of said polymorphism; and a method for the diagnosis of said polymorphism for determining the status of a human.

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 8837

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-03-2004

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9740462	A	30-10-1997	AU 2734197 A	12-11-1997
			EP 0897567 A2	24-02-1999
			JP 2000508912 T	18-07-2000
			WO 9740462 A2	30-10-1997
US 6133434	A	17-10-2000	US 6509163 B1	21-01-2003
WO 9929660	A	17-06-1999	AT 234274 T	15-03-2003
			AU 746716 B2	02-05-2002
			AU 1791499 A	28-06-1999
			BR 9813368 A	03-10-2000
			CA 2312889 A1	17-06-1999
			CN 1280560 T	17-01-2001
			DE 69812159 D1	17-04-2003
			DE 69812159 T2	18-12-2003
			DK 1036058 T3	30-06-2003
			EE 200000320 A	15-08-2001
			EP 1036058 A1	20-09-2000
			ES 2195433 T3	01-12-2003
			HK 1028594 A1	05-09-2003
			HU 0100431 A2	30-07-2001
			JP 2001525391 T	11-12-2001
			NO 20002785 A	01-08-2000
			NZ 504375 A	29-08-2003
			PL 340890 A1	12-03-2001
			PT 1036058 T	31-07-2003
			RU 2197477 C2	27-01-2003
			WO 9929660 A1	17-06-1999
			SK 8412000 A3	07-11-2000
			TR 200001558 T2	23-10-2000
			US 6242470 B1	05-06-2001

EPO FORM P0159

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)